Online inquiry

IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5080MR)

This product GTTS-WQ5080MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF2RA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001161529.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1438
UniProt ID P15509
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5080MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3395MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ3870MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ10503MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ15833MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ10073MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ6147MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-675
GTTS-WQ4244MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ11799MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW